9:54 AM
 | 
Nov 20, 2017
 |  BC Extra  |  Clinical News

Acorda discontinues PD candidate tozadenant

Acorda Therapeutics Inc. (NASDAQ: ACOR) discontinued development of Parkinson's disease candidate tozadenant (SYN115) "based on new information" related to cases of agranulocytosis disclosed last week that were possibly related to tozadenant and in some cases associated with sepsis and death (see BioCentury Extra, Nov. 15).

Based on the new undisclosed information,...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >